Latest Mergers And Acquisitions News

Heavy Rare Earths Limited (ASX:HRE) advanced its uranium exploration footprint in South Australia with a key asset acquisition and bolstered its balance sheet through a $2.46 million capital raise during the December 2024 quarter.

MyEco Group Ltd has reported a robust 32% increase in sustainable product sales for Q2 FY25, driven by a remarkable 156% jump in MyEco branded product sales. Despite negative operating cash flow due to inventory build-up, the company is poised for continued growth in the second half of the fiscal year.

Capricorn Metals delivered a robust December quarter with rising gold production, record cash flow, and strategic expansions, positioning itself strongly for FY25 targets.

Beforepay Group has reported a strong Q2 FY25 with record revenue exceeding $10 million and a growing active user base, while introducing its new Personal Loan product.

Lark Distilling Co. Ltd reported a 7% increase in net sales revenue for Q2FY25, driven by strong growth in direct-to-consumer, global travel retail, and export channels despite domestic B2B challenges. The company is advancing its brand restage and maintaining solid cash reserves.

Articore Group reveals a strategic restructure delivering significant cost savings and improved margins, even as marketplace revenue continues to decline. The launch of a new product, Dashery, aims to diversify revenue streams.

Intelligent Monitoring Group Limited has reaffirmed its FY25 adjusted EBITDA guidance above $38 million, reporting a robust $7.9 million operating cash flow for the first half of 2025. The company is advancing its strategic acquisitions and launching innovative video guarding services poised to disrupt the security sector.

Change Financial Limited reported a robust Q2 FY25 with revenue surging 53% year-on-year, driven by its expanding PaaS platform, while strategically exiting its loss-making US operations to sharpen focus on Australia and New Zealand.

Doctor Care Anywhere delivered positive cash flow and revenue growth at the top of guidance in Q4 2024, while navigating a strategic shift with new leadership appointments and the closure of secondary care pathways.

Island Pharmaceuticals reports promising safety and anti-dengue activity in its Phase 2a trial of ISLA-101 and has commenced the Phase 2b therapeutic arm, backed by a fresh A$3.5 million capital raise.

Alcidion Group Limited reported robust Q2 FY25 sales of $13.1 million and improved cash flow, reinforcing its forecast to achieve EBITDA and cashflow positivity by the end of FY25.

Wisr has reported a robust Q2FY25 with loan originations surging 77% year-on-year to $93.5 million, alongside improving credit metrics and a well-capitalised balance sheet.